David Albala, MD and Judd W. Moul, MD consider the impact that COVID-19 has had on the clinical experience of patients with prostate cancer and share personal insights regarding telehealth and patient compliance.
At the American Society of Clinical Oncology Genitourinary Cancer Symposium, Judd W. Moul, MD, a urologist at Duke Cancer Institute, offered his insights on …
Purpose:Transrectal prostate biopsy has come under scrutiny due to potential for postbiopsy infections and transperineal prostate biopsy is being offered as the safer alternative. However,…
Available data support the improved detection performance and selectivity of NGI modalities versus conventional imaging techniques; however, limited clinical evidence exists demonstrating the application of…
Abstract/Video/T. Leon Howard Case Submissions Welcome Guest Submission Dates System is Open Open: June 21, 2023 12:00 AM (Central Time U.S. & Canada) Closes:…
The rule includes a proposed unadjusted national average payment rate of US$21,376.53 for the device in 2024.
Researchers may be able to use imaging mass cytometry to capture and classify the tumor-immune evasion cell networks in clear cell renal cell carcinoma.
The PARP inhibitor olaparib demonstrated antitumor activity in patients with BAP1-mutated renal cell carcinoma.
“For this population of patients…testosterone replacement therapy does appear to be safe from a cardiovascular standpoint,” says A. Michael Lincoff, MD.
“I think one of the hottest topics for advocacy right now relates to reimbursement for telemedicine,” says Amanda C. North, MD.
“We are now doing more testing on the RNA side,” says Brittany M. Szymaniak, PhD, CGC.
